The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727

被引：1
作者：
Salam, Amar M. [1 ]
机构：
[1] Hamad Med Corp, Doha, Qatar
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2012年 / 21卷 / 10期
关键词：
dyslipidemia; PCSK9; SAR236553/REGN727; trial; LDL CHOLESTEROL; MICE; HYPERCHOLESTEROLEMIA; STATINS; TARGET;
D O I：
10.1517/13543784.2012.707193
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease that has recently emerged as a potential target for the treatment of hypercholesterolemia. SAR236553/REGN727 is a highly specific monoclonal antibody to PCSK9 that significantly reduced LDL cholesterol levels in healthy volunteers and in subjects with hypercholesterolemia in three Phase-I studies. It was subsequently tested in a recent Phase-II study in patients with primary hypercholesterolemia with impressive results. In this report the trial is discussed along with the significance of the results in guiding further research in PCSK9 inhibition.
引用
收藏
页码：1585 / 1588
页数：4
相关论文
共 11 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] Pharmacological strategies for lowering LDL cholesterol: statins and beyond
    Brautbar, Ariel
    Ballantyne, Christie M.
    [J]. NATURE REVIEWS CARDIOLOGY, 2011, 8 (05) : 253 - 265
  • [3] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    Cohen, JC
    Boerwinkle, E
    Mosley, TH
    Hobbs, HH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) : 1264 - 1272
  • [4] PCSK9: an emerging target for treatment of hypercholesterolemia
    Duff, Christopher J.
    Hooper, Nigel M.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (02) : 157 - 168
  • [5] The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
    Hooper, Amanda J.
    Marais, A. David
    Tanyanyiwa, Donald M.
    Burnett, John R.
    [J]. ATHEROSCLEROSIS, 2007, 193 (02) : 445 - 448
  • [6] Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes
    Horton, JD
    Shah, NA
    Warrington, JA
    Anderson, NN
    Park, SW
    Brown, MS
    Goldstein, JL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (21) : 12027 - 12032
  • [7] Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
    Lagace, Thomas A.
    Curtis, David E.
    Garuti, Rita
    McNutt, Markey C.
    Park, Sahng Wook
    Prather, Heidi B.
    Anderson, Norma N.
    Ho, Y. K.
    Hammer, Robert E.
    Horton, Jay D.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (11) : 2995 - 3005
  • [8] Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
    Park, SW
    Moon, YA
    Horton, JD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (48) : 50630 - 50638
  • [9] PCSK9 function and physiology (vol 49, pg 1303, 2008)
    Peterson, Andrew S.
    Fong, Loren G.
    Young, Stephen G.
    [J]. JOURNAL OF LIPID RESEARCH, 2008, 49 (07) : 1595 - 1599
  • [10] Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
    Rashid, S
    Curtis, DE
    Garuti, R
    Anderson, NN
    Bashmakov, Y
    Ho, YK
    Hammer, RE
    Moon, YA
    Horton, JD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (15) : 5374 - 5379
12